Roche has posted a record set of financial figures for 2007 which show that revenues rose 10% to 46.13 billion Swiss francs, while net income soared 25% to 11.44 billion francs, or just shy of $10.50 billion.

Its pharmaceuticals sales, excluding the contribution made by subsidiaries Genentech and Chugai, were up 11% to 22.97 billion francs, driven by sales of the division’s oncology products. Globally, MabThera/Rituxan (rituximab) for non-Hodgkin’s lymphoma grew 15% to 5.52 billion francs, while sales of Herceptin (trastuzumab) grew 23% to 4.85 billion francs. Avastin (bevacizumab) recorded an increase of 41% to 4.11 billion francs, while Tarceva (erlotinib) sales grew by 31% to 1.06 billion francs.

The transplantation products, CellCept (mycophenolate mofetil) and Valcyte (valganciclovir)/Cymevene (ganciclovir) rose 10% and 12% respectively to $2.01 billion and $542 million. Its hepatitis C treatment Pegasys (peginterferon alfa) increased 11% to 1.64 billion francs, while osteoporosis drug Boniva/Bonviva (ibandronic acid) also put in a good showing, climbing 85% to 887 million francs.

However there was disappointment when it came to sales of the influenza Tamiflu (oseltamivir) which fell back 19% globally to 2.09 billion francs. The decline was expected, as most existing pandemic stockpiling orders have now been fulfilled and Tamiflu sales for next year are expected to fall even further.

The results beat analysts’ expectations and Roche is predicting more of the same over the next few years. Despite the anticipated lower Tamiflu sales and “significantly higher R&D spending”, Roche expects earnings to “remain at least in line” with 2007. The Basle-based group anticipates continued strong growth in 2009 and 2010, helped by the launch of rheumatoid arthritis drug Actemra (tocilizumab) and the anaemia treatment Mircera (methoxy polyethylene glycol-epoetin beta).